1005402-20-9

Basic information

• Product Name: 6-(4-hydroxyphenyl)-2-methyl-2H-pyridazin-3-one
• Synonyms: 6-(4-hydroxyphenyl)-2-methyl-2H-pyridazin-3-one
• CAS NO: 1005402-20-9
• Molecular Weight: 202.213
• Mol File: 1005402-20-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-(4-hydroxyphenyl)-2-methyl-2H-pyridazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-hydroxyphenyl)-2-methyl-2H-pyridazin-3-one(1005402-20-9)
• EPA Substance Registry System: 6-(4-hydroxyphenyl)-2-methyl-2H-pyridazin-3-one(1005402-20-9)

Safety Data

• Hazardous Substances Data: 1005402-20-9(Hazardous Substances Data)

Upstream product

• 15118-67-9 ethyl 3-(4-methoxybenzoyl)-propionate 
• 33347-88-5 2-methyl-6-(4-methoxyphenyl)-4,5-dihydro-3(2H)-pyridazinone 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 
• 2472-78-8 6-(4-methoxyphenyl)-2-methyl-2H-pyridazin-3-one 

Downstream Products

• 1005402-21-0 6-[4-(3-chloropropoxy)phenyl]-2-methyl-2H-pyridazin-3-one 
• 1333420-46-4 C₁₅H₁₈N₂O₃ 
• 1333420-51-1 C₁₅H₁₈N₂O₃ 
• 1005401-46-6 2-methyl-6-{4-[3-((R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one hydrochloride 

Relevant articles and documents

4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity

Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/ inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metaboli

Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity

H3R structure-activity relationships on a novel class of pyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modifications of the pyridazinone core, central phenyl ring and linker led to the identification of molecules wi

Pyridizinone derivatives

The present invention provides compounds of formula (I*): their use as H3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.